These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34180955)

  • 1. Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market.
    Levy J; Chowdhury ZM; Socal MP; Trujillo AJ
    JAMA Intern Med; 2021 Oct; 181(10):1405-1407. PubMed ID: 34180955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015-2018).
    Agirrezabal I; Sánchez-Iriso E; Mandar K; Cabasés JM
    Diabetes Care; 2020 Aug; 43(8):1767-1773. PubMed ID: 32527798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
    Godman B; Wladysiuk M; McTaggart S; Kurdi A; Allocati E; Jakovljevic M; Kalemeera F; Hoxha I; Nachtnebel A; Sauermann R; Hinteregger M; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Slabý J; Nejezchlebova R; Krulichová IS; Laius O; Selke G; Langner I; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuolienė K; Gulbinovič J; Bonanno PV; Rutkowski J; Ingeberg S; Melien Ø; Mardare I; Fürst J; MacBride-Stewart S; Holmes C; Pontes C; Zara C; Pedrola MT; Hoffmann M; Kourafalos V; Pisana A; Banzi R; Campbell S; Wettermark B
    Biomed Res Int; 2021; 2021():9996193. PubMed ID: 34676266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.
    Hernandez I; Gellad WF
    J Manag Care Spec Pharm; 2020 Feb; 26(2):154-159. PubMed ID: 32011961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In brief: Semglee - insulin glargine interchangeable with Lantus.
    Med Lett Drugs Ther; 2021 Oct; 63(1634):159-160. PubMed ID: 34550958
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study.
    Shingaki T; Taki K; Koyanagi M; Nagaoka S; Yoshizawa K; Oki N; Yoshikawa A; Imaoka T
    Curr Med Res Opin; 2020 Jun; 36(6):947-958. PubMed ID: 32271092
    [No Abstract]   [Full Text] [Related]  

  • 7. The impact of biosimilar insulins on the diabetes landscape.
    White J; Wagner A; Patel H
    J Manag Care Spec Pharm; 2022 Jan; 28(1):91-98. PubMed ID: 34726499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of an intervention strategy in the biosimilar glargine prescription pattern in primary care].
    Saborido-Cansino C; Santos-Ramos B; Carmona-Saucedo C; Rodríguez-Romero MV; González-Martín A; Palma-Amaro A; Rojas-Lucena IM; Almeida-González C; Sánchez-Fidalgo S
    Aten Primaria; 2019; 51(6):350-358. PubMed ID: 29861115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar Insulin and Costs: What Can We Expect?
    Heinemann L
    J Diabetes Sci Technol; 2015 Sep; 10(2):457-62. PubMed ID: 26350722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
    Russel-Szymczyk M; Valov V; Savova A; Manova M
    BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018.
    Hernandez I; Good CB; Shrank WH; Gellad WF
    JAMA; 2019 Apr; 321(16):1627-1629. PubMed ID: 30907933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction of biosimilar insulins in Europe.
    Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C
    Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The price paradox of biosimilar-like long-acting insulin.
    Mouslim MC; Rashidi ES; Levy JF; Socal MP; Trujillo AJ
    Am J Manag Care; 2022 Nov; 28(11):e405-e410. PubMed ID: 36374658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The cardiovascular outcome is critical].
    Stiefelhagen P
    MMW Fortschr Med; 2016 Feb; 158(3):68. PubMed ID: 27119710
    [No Abstract]   [Full Text] [Related]  

  • 15. Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.
    Sun B; Sengupta N; Rao A; Donnelly C; Waichale V; Roy AS; Ramaswamy S; Pathak D; Bowsher RR; Raiter Y; Aubonnet P; Barve A
    BMC Endocr Disord; 2021 Jun; 21(1):129. PubMed ID: 34174848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union].
    Altman JJ; Chevalier N; Delemer B; Travert F; Benabbad I
    Presse Med; 2018 Oct; 47(10):854-866. PubMed ID: 30262205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar insulins are coming: what they are, what you need to know.
    Edelman S; Polonsky WH; Parkin CG
    Curr Med Res Opin; 2014 Nov; 30(11):2217-22. PubMed ID: 25105307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications.
    Haque M; Islam S; Kamal ZM; Akter F; Jahan I; Rahim MSA; Sultana N; Alam AM; Munzur-E-Murshid ; Halim-Khan MA; Deeba F; Bakar MA; Nahar S; Mozaffor M; Urmi UL; Saikat TR; Islam MZ; Haque M; Iqbal S; Hossain MM; Naher N; Allocati E; Godman B
    Hosp Pract (1995); 2021 Oct; 49(4):266-272. PubMed ID: 33734004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar products are not bioidentical.
    Garber AJ
    J Diabetes; 2015 Mar; 7(2):153-4. PubMed ID: 25395269
    [No Abstract]   [Full Text] [Related]  

  • 20. Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway.
    Rasmussen JT; Ipema HJ
    Ann Pharmacother; 2019 Feb; 53(2):204-210. PubMed ID: 30122087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.